Hypertrophic Obstructive Cardiomyopathy Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Comparative Evaluation of Alcohol Septal Ablation: Left Anterior Descending vs. Non-left Anterior Descending Artery Approaches
This study aimed to compare effectiveness and safety between ASA performed using a septal branch arising from a non-LAD artery and a branch arising from the LAD artery. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 22, 2024 Category: Cardiology Authors: Yoshihiro Harano, Yuki Sahashi, Yoshiaki Kawase, Hitoshi Matsuo Source Type: research

Resection of hypertrophic papillary muscles and mitral valve replacement in a patient with midventricular hypertrophic obstructive cardiomyopathy – a new approach
Midventricular hypertrophic obstructive cardiomyopathy (HOCM) is characterized by hypertrophy of the interventricular septum (IVS) and - in rare cases - of the papillary muscles (PM), which subsequently can ca... (Source: Journal of Cardiothoracic Surgery)
Source: Journal of Cardiothoracic Surgery - February 22, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Julian J. Berg, Jan Eckstein, Marcus-Andr é Deutsch, Jan F. Gummert and Masatoshi Hata Tags: Case Report Source Type: research

Comparative Evaluation of Alcohol Septal Ablation: Left Anterior Descending Versus Nonleft Anterior Descending Artery Approaches
This study aimed to compare the effectiveness and safety between ASA performed using a septal branch arising from a non-LAD artery and a branch arising from the LAD artery. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 22, 2024 Category: Cardiology Authors: Yoshihiro Harano, Yuki Sahashi, Yoshiaki Kawase, Hitoshi Matsuo Source Type: research

Comparative Evaluation of Alcohol Septal Ablation: Left Anterior Descending Versus Non-left Anterior Descending Artery Approaches
This study aimed to compare the effectiveness and safety between ASA performed using a septal branch arising from a non-LAD artery and a branch arising from the LAD artery. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 22, 2024 Category: Cardiology Authors: Yoshihiro Harano, Yuki Sahashi, Yoshiaki Kawase, Hitoshi Matsuo Source Type: research

Posterior Papillary Muscle Suspension for Treating Systolic Anterior Motion in Hypertrophic Obstructive Cardiomyopathy
Ann Thorac Cardiovasc Surg. 2024;30(1). doi: 10.5761/atcs.nm.23-00176.ABSTRACTSystolic anterior motion of the anterior mitral leaflet can persist after ventricular septal myectomy for obstructive hypertrophic cardiomyopathy, resulting in residual pressure gradients and mitral regurgitation. However, additional procedures for systolic anterior motion involving mitral valve leaflet suturing and resection may lead to future valve disease. Therefore, we adopted posterior papillary muscle suspension, a subvalvular procedure for functional mitral regurgitation, to treat systolic anterior motion without directly intervening in th...
Source: Annals of Thoracic and Cardiovascular Surgery - January 31, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Taiki Ito Satoru Wakasa Koji Sato Shinji Abe Taro Minamida Source Type: research

Bi-atrial arrhythmogenic substrate in patients with hypertrophic obstructive cardiomyopathy
Atrial fibrillation (AF) in patients with hypertrophic obstructive cardiomyopathy (HOCM) may be caused by a primary atrial myopathy. Whether HOCM-related atrial myopathy affects mainly electrophysiological properties of the left atrium (LA) or also the right atrium (RA) has never been investigated. (Source: Heart Rhythm)
Source: Heart Rhythm - January 19, 2024 Category: Cardiology Authors: Nawin L. Ramdat Misier, Jorik H. Amesz, Yannick J.H.J. Taverne, Hoang Nguyen, Mathijs S. van Schie, Paul Knops, Arend F.L. Schinkel, Peter L. de Jong, Bianca J.J.M. Brundel, Natasja M.S. de Groot Source Type: research

Biatrial arrhythmogenic substrate in patients with hypertrophic obstructive cardiomyopathy
Atrial fibrillation (AF) in patients with hypertrophic obstructive cardiomyopathy (HOCM) may be caused by a primary atrial myopathy. Whether HOCM-related atrial myopathy affects mainly electrophysiological properties of the left atrium (LA) or also the right atrium (RA) has never been investigated. (Source: Heart Rhythm)
Source: Heart Rhythm - January 19, 2024 Category: Cardiology Authors: Nawin L. Ramdat Misier, Jorik H. Amesz, Yannick J.H.J. Taverne, Hoang Nguyen, Mathijs S. van Schie, Paul Knops, Arend F.L. Schinkel, Peter L. de Jong, Bianca J.J.M. Brundel, Natasja M.S. de Groot Source Type: research

Exploring the Connection Between Relaxed Myosin States and the Anrep Effect
Circ Res. 2024 Jan 5;134(1):117-134. doi: 10.1161/CIRCRESAHA.123.323173. Epub 2024 Jan 4.ABSTRACTThe Anrep effect is an adaptive response that increases left ventricular contractility following an acute rise in afterload. Although the mechanistic origin remains undefined, recent findings suggest a two-phase activation of resting myosin for contraction, involving strain-sensitive and posttranslational phases. We propose that this mobilization represents a transition among the relaxed states of myosin-specifically, from the super-relaxed (SRX) to the disordered-relaxed (DRX)-with DRX myosin ready to participate in force gene...
Source: Circulation Research - January 4, 2024 Category: Cardiology Authors: Vasco Sequeira Christoph Maack Gert-Hinrich Reil Jan-Christian Reil Source Type: research

Left Atrial Functional Assessment in Hypertrophic Cardiomyopathy Patients Receiving Mavacamten
Development of atrial myopathy and reduced atrial compliance are associated to adverse outcomes including worsening heart failure, stroke, and all-cause mortality. Left atrial (LA) dysfunction in hypertrophic obstructive cardiomyopathy (HOCM) is often attributed to left ventricular diastolic dysfunction in the presence of elevated filling pressures. It has been suggested that the novel cardiac myosin inhibitor (Mavacamten) will help improve diastolic function, however detailed assessments are lacking. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Janelle Muuse, Kirtan Patel, Cassandra Price, Cassady Palmer, Natalie Swope, Christian Schmidt, Brittney Johnson, Mohammad Akhtar, Wojciech Mazur, Ankit Bhatia Tags: 13 Source Type: research

Real World Impact Of Mavacamten In Patients With Hypertrophic Obstructive Cardiomyopathy: A Retrospective Single Center Experience In A Predominantly Asian Cohort
Mavacamten is a novel medication inhibiting the function of cardiac myosin, and has shown promise in improving left ventricular outflow tract obstruction, heart failure symptoms, and quality of life in patients with hypertrophic obstructive cardiomyopathy (HCM). The EXPLORER-HCM trial established this efficacy in an almost exclusively Caucasian population on a background of concomitant negative inotropic therapy with either calcium channel blockers (CCB) or beta blockers) BB). Some recent data suggests that negative inotropic therapy could impair the effect of mavacamten. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Kevin Benavente, Jesus Pino, Dipanjan Banerjee Tags: 424 Source Type: research